In our most recent blog post, our Dutch team discusses a new ground-breaking policy, short-formed as 'Fast'. This programme aims to accelerate the relatively slow, incremental, and high-priced innovation in the pharmaceutical field.
Read more about this new policy here:
But do we think this initiative is enough? Share your thoughts with us below